INOVIO PHARMACEUTICALS Forum: Community User: gerry

20$

https://www.marketwatch.com/investing/stock/ino

Jetzt gehts hoch

🙈

Phil, das ist alt😅

$5 millions from CEPI

Guats Nächtle 😎

Dr. J. Joseph Kim, INOVIO's President and Chief Executive Officer, said, "The second quarter further demonstrated the versatility and potential of INOVIO's DNA medicines platform to meet urgent global health needs. In addition to advancing our DNA vaccine INO-4800 to combat the ongoing COVID-19 pandemic, INOVIO presented encouraging results for one of the most devastating and difficult-to-treat cancers, GBM. We believe our DNA medicines are ideally suited to safely drive robust immune responses across infectious diseases and cancer, and we look forward to publishing our latest INO-4800 data, starting our Phase 2/3 COVID-19 clinical study in the U.S. in September, and expanding the manufacturing capacity to produce at least 100 million doses of INO-4800 in 2021 via our growing global coalition of partners and funders."

Jetzt sogar im Plus 😅 naja bis morgen 1530 sollte man den Kurs nicht beachten ☺️ Guts Nächtle

Hoffe ich doch 😏 das bis jetzt ist kalter Kaffee haben wir hier schon alles diskutiert

Vielleicht im Call mehr Infos.

INOVIO Second Quarter Highlights - INO-4800 U.S. Phase 1 clinical manuscript with full clinical data currently under-going peer-review for publication at a top medical journal; INO-4800 was generally safe and well-tolerated in all participants with only 6 treatment related Grade 1 (lowest) AEs - 100% of trial participants demonstrated overall immune responses - 95% had seroconverted by antibody response overall; - Nearly 90% generated strong T cell responses, including CD8+ T cell responses - Secured $71 million from U.S. Department of Defense to scale up manufacture of CELLECTRA® 3PSP smart device and procurement of CELLECTRA® 2000 - Reported favorable INO-4800 animal challenge data in mouse and non-human primate (NHP) studies; NHP challenge data at 13 weeks post last immunization showed robust memory immune responses and protection from virus replication in both nasal passages and lower lungs - INO-4800 selected by U.S. Operation Warp Speed for COVID-19 non-human primate challenge study - Expanded INO-4800 DNA manufacturing agreement with Richter-Helm and CEPI to support large-scale manufacturing; currently expanding manufacturing consortium and on track to meet goal of producing at least 100 million INO-4800 doses in 2021 via growing global coalition of partners and funders - Phase 1/2 INO-4800 trials for COVID-19 approved in South Korea and China - Presented positive 12-month overall survival efficacy data demonstrating 85% survival rate for DNA immunotherapy candidate INO-5401 in treatment of glioblastoma multiforme (GBM) at American Society of Clinical Oncology (ASCO) Annual Meeting - Reported positive Interim Phase 2 results for DNA immunotherapy candidate VGX-3100 in treating HPV-associated anal and vulvar dysplasia; VGX-3100 REVEAL 1 pivotal Phase 3 data for HPV-associated cervical dysplasia on track to be reported in 4Q2020 - INO-3107, a treatment of recurrent respiratory papillomatosis (RRP), a rare, debilitating disease caused by HPV infection, received Orphan Disease designation by the FDA; Phase 1/2 clinical trial initiated Investor Call Today at 4:30 PM ET

Aua das wird teuer

FAC das ist ja alles bekannt was du reingestellt hast der Markt möchte immer noch News hören. Haben die da nichts dabei

Aua 15€ 🙈

Die wollen das du verkaufst